Facebook
Twitter
LinkedIn
Forward
Over the last decade, the FDA has approved five new medications for the treatment of obesity. The latest edition, semaglutide, published impressive weight loss results and we are just beginning.
|
Obesity Medicine 2023 - Spring Obesity Summit
|
Selecting the correct on label or off label medication to treat obesity can be confusing. The acronym RXAOM provides a framework for individualizing the selection process.
|
Here we are! At the Obesity the Tipping Point: the critical point in a process or system beyond which a significant and often unstoppable effect or change takes place.
|
Demand for pharmacotherapy has increased considerably with the introduction of newer anti-obesity medications (AOM’s).
|
This session will inform HCPs on the tirzepatide molecule, design of the SURMOUNT global trial program for the treatment of obesity and overweight, and safety and efficacy data disclosure for SURMO
|
Obesity is a metabolic disease that requires lifelong lifestyle changes and in many patients who are overweight or obese, prescription medication.
|
This session will be an overview of assessment and treatment options for children with special needs or medical complexity who also suffer from obesity.
|
As published and described in Obesity Pillars (i.e., the official journal of the Obesity Medicine Association), excessive weight reduction is an emerging challenge that sometimes arises with approv
|
This session will examine the use of on-label anti-obesity pharmacotherapy to treat obesity.
|